GVHD,Acute

18 registered clinical trials studyying GVHD,Acute — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease) NCT07509749	Daihong Liu	Phase 2
Recruiting	Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) NCT07340723	Daihong Liu	Phase 2
Recruiting	Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant NCT06315309	University of Alabama at Birmingham	Phase 2
Recruiting	Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transpla NCT06462365	Tr1X, Inc.	Phase 1
Unknown	Safety and Efficacy Study of hAESCs Therapy for aGVHD NCT06164288	Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China	Phase 1
Not Yet Recruiting	Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis NCT05855707	Central Hospital, Nancy, France	Phase 1
Withdrawn	Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD) NCT05443464	Ossium Health, Inc.	Phase 1
Recruiting	CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease NCT05718791	Henry Ford Health System	—
Unknown	Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD) NCT05401955	University of Salamanca	N/A
Unknown	MAP-guided Preemptive Therapy of aGvHD NCT05368181	Sichuan University	Phase 2
Recruiting	Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT NCT04118556	Mats Remberger	Phase 2
Terminated	A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host NCT04220632	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1 / Phase 2
Completed	A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD NCT03763318	Equillium	Phase 1 / Phase 2
Completed	CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease NCT03605927	H. Lee Moffitt Cancer Center and Research Institute	Phase 1
Completed	PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT NCT04118075	Shanghai Jiao Tong University School of Medicine	Phase 2
Completed	Analysis of Intestinal Defensin Expression in Acute GVHD NCT04522843	University of Freiburg	—
Unknown	To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Dise NCT03371667	Assistance Publique - Hôpitaux de Paris	Phase 3
Unknown	Role of aGVHD Biomarkers on aGVHD Risks NCT04284904	Chinese PLA General Hospital	—